About Us
Our Pipeline
Recent News
Contact Us
CN
Stay informed about our latest updates.
Recent News
September 29, 2021
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma
August 02, 2021
Overland Pharmaceuticals Appoints Roger Luo, Ph.D. as Chief Development Officer
June 21, 2021
Allogene Overland Biopharm Appoints Shuyuan Yao as Chief Executive Officer
April 06, 2021
Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer
December 15, 2020
Allogene Therapeutics and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize AlloCAR T™ Cell Therapies
December 14, 2020
ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore
December 09, 2020
Overland Pharmaceuticals Debuts as Premier Biopharmaceutical Company to Bring Innovative Medicines to Asia and Worldwide
Scroll to top